| Co-Investigator(Kenkyū-buntansha) |
林 良雄 東京薬科大学, 薬学部, 教授 (10322562)
吉村 亮一 東京医科歯科大学, 医歯(薬)学総合研究科, 教授 (40302864)
戒田 篤志 東京医科歯科大学, 医歯(薬)学総合研究科, 助教 (40632097)
岡本 裕之 国立研究開発法人国立がん研究センター, その他部局等, その他 (90595729)
|
|---|
| Budget Amount *help |
¥15,860,000 (Direct Cost: ¥12,200,000、Indirect Cost: ¥3,660,000)
Fiscal Year 2016: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Outline of Final Research Achievements |
Low dose-rate brachtytherapy is a definitive radiotherapy for early stage oral cancer. Au-198 grains are often used for the therapy; however, their supply has been insufficient since The Great East Japan Earthquake. The objective of this study was to examine whether Au-198 grains could be replaced by I-125 seeds usually used for the prostate cancer treatment. For this purpose, three dimensional absorption dose distribution was simulated and temporo-spatial kinetics of G2 arrest was analyzed. When applied to mold therapy using transient treatment instead of eternal implant, we tentatively propose that Au-198 grains could be replaced by I-125 seeds when ten times more number of I-125 seeds are used compared with that of Au-198 grains.
|
